PDUFA VII: US FDA Will Offer Additional Meetings To Boost Rare Disease Endpoint Development
If they reach a public disclosure agreement, a handful of sponsors will be admitted to a new pilot program that allows four meetings with the FDA on rare disease endpoint issues.
You may also be interested in...
Program growth beyond supplements will be determined after the agency gains experience with STAR program, PhRMA executive tells the Pink Sheet.
Head of Office of New Drugs highlights programs being established under PDUFA VII that could help overcome obstacles in drug development.
Latest iteration of the Prescription Drug User Fee Act agreement negotiated by US FDA and the pharmaceutical industry continues the trend to ever larger sets of goals and commitments as part of the reauthorization process.